17195-26-5

Basic information

• Product Name: leucyl-alanyl-glycyl-valine
• Synonyms: leucyl-alanyl-glycyl-valine
• CAS NO: 17195-26-5
• Molecular Formula: C16H30 N4 O5
• Molecular Weight: 358.43
• Mol File: 17195-26-5.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 694.6°C at 760 mmHg
• Flash Point: 373.9°C
• Appearance: /
• Density: 1.153g/cm³
• Vapor Pressure: 4E-21mmHg at 25°C
• Refractive Index: 1.503
• CAS DataBase Reference: leucyl-alanyl-glycyl-valine(CAS DataBase Reference)
• NIST Chemistry Reference: leucyl-alanyl-glycyl-valine(17195-26-5)
• EPA Substance Registry System: leucyl-alanyl-glycyl-valine(17195-26-5)

Safety Data

• Hazardous Substances Data: 17195-26-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C16H30N4O5/c1-8(2)6-11(17)15(23)19-10(5)14(22)18-7-12(21)20-13(9(3)4)16(24)25/h8-11,13H,6-7,17H2,1-5H3,(H,18,22)(H,19,23)(H,20,21)(H,24,25)

Upstream product

• 4070-48-8 L-Valine methyl ester 
• 29022-11-5 N-(fluoren-9-ylmethoxycarbonyl)glycine 
• 35661-60-0 Fmoc-Leu-OH 
• 35661-39-3 N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-alanine 
• 101366-58-9 2,4,5-Trichlorophenyl-3'-4''-(Fmoc-valyloxymethyl)phenoxy propionate 
• 56-41-7 L-alanin 
• 72-18-4 L-valine 
• 56-40-6 glycine 
• 4530-20-5 BOC-glycine 
• 15761-38-3 L-N-Boc-Ala 
• 61165-82-0 Boc-Val-OMPA 
• 13139-15-6 Boc-Leu-OH 
• 70626-37-8 9-fluorenylmethyloxycarbonyl-L-leucine anhydride 
• 69355-80-2 Z-Leu-Ala-Gly-Val-OMe 

Relevant articles and documents

REMOVAL OF 9-FLUORENYLMETHYLOXYCARBONYL (Fmoc) GROUP WITH TERABUTYLAMMONIUM FLUORIDE

Tetrabutylammonium fluoride in N,N-dimethylformamide (DMF) is an effective alternative to the piperidine reagent for the removal of 9-fluorenylmethyloxycarbonyl (Fmoc) group in the solid phase peptide synthesis.

ARENESULPHONYLTRIAZOLIDES AS CONDENSING REAGENTS IN SOLID PHASE PEPTIDE SYNTHESIS

Results on the use of 1-arenesulphonyl-3-nitro-1,2,4-triazoles and N-methylimidazole or 4-morpholinopyridine-1-oxide as reagents for peptide bond formation on a solid support are reported.

METHOD FOR PREPARING PEPTIDES

The invention relates to a method for preparing peptides comprising the step of forming a peptide bond wherein the carboxyl group of a first amino acid or first peptide is activated and an amino group of the first activated amino acid or first peptide is protected by a protecting group having a water-solubility enhancing group and the activated carboxyl group of the first amino acid or first peptide is reacted with an amino group of a second amino acid or second peptide wherein said carboxyl group of the first amino acid or first peptide is activated in the absence of the second amino acid or second peptide. The invention further relates to peptides comprising a protecting group having a water-solubility enhancing group being bound to the amino group and an activated or free carboxyl group.

Use of HCG derived peptides in the treatment of iatrogenic diseases

The invention relates to the field of (veterinary) medicine and to the treatment of subjects (be it man or animal) that suffer from iatrogenic disease, i.e. experience problems or complications resulting from a medical treatment. The invention provides a

Compositions for mucosal and oral administration comprising hCG fragments

The invention relates to the field of immunology, more specifically to the field of immune-mediated disorders such as allergies, auto-immune disease, transplantation-related disease and other inflammatory diseases. The invention in particular relates to t